Sanjay Mistry

Sanjay Mistry is a senior investment professional and board member at TRex Bio, a biotechnology company. He brings extensive experience in venture investments and new company creation within the pharmaceutical and biotechnology sectors.

Professional Background

Sanjay Mistry currently serves as the Vice President of Venture Investments and New Company Creation at Johnson & Johnson Innovation – JJDC Inc.1 In this role, he focuses on identifying and developing new investment opportunities in the life sciences industry.

Board Positions

Mistry holds several board positions, including:

• Director on the Board of Directors at TRex Bio3
• Director at Rapport Therapeutics2
• Observer at Manifest Technologies2

Education

Sanjay Mistry has a strong academic background in pharmacology and biology:

• PhD in Pharmacology from the University of Aberdeen, UK4
• MSc in Clinical Pharmacology from the University of Aberdeen, UK4
• BSc in Applied Biology/Biomedical Sciences4

Recent Developments

In June 2024, Mistry shared news about TRexBio's collaboration with Lilly, announcing the initiation of a Phase 1 study of TRB-051 for autoimmune and inflammatory diseases.5 This demonstrates his active involvement in the company's strategic partnerships and drug development progress.

Sanjay Mistry's expertise in venture investments, coupled with his scientific background, makes him a valuable asset to TRex Bio's board of directors, contributing to the company's growth and development in the biotechnology sector.